KRRO NASDAQ
Korro Bio, Inc.
1W: +1.1%
1M: -19.9%
3M: +0.8%
YTD: +39.1%
1Y: -30.8%
3Y: -37.8%
5Y: -97.4%
$11.61
+0.41 (+3.66%)
Weekly Expected Move ±8.7%
$8
$9
$10
$11
$12
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (27)
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro to Participate in Upcoming Investor Conferences
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Korro Bio (NASDAQ:KRRO) Stock Price Down 0.8% – Should You Sell?
Top 5 Insider Buys From Q1: Buy, Sell, or Hold in Q2?
JPMorgan Chase & Co. Buys 196,079 Shares of Korro Bio, Inc. $KRRO
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Recommendation of “Moderate Buy” by Brokerages
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
12 Health Care Stocks Moving In Friday's Pre-Market Session
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
12 Health Care Stocks Moving In Thursday's After-Market Session
Korro Bio GAAP EPS of -$12.48 misses by $3.43, revenue of $6.4M beats by $1M
United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains?
Korro announces oversubscribed $85 million private placement
Korro Announces Oversubscribed $85 Million Private Placement
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Hold” from Analysts
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?
Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE
Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript
Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Korro to Host Virtual Analyst Day on January 27, 2026
Korro Bio (NASDAQ:KRRO) Shares Down 5.9% – Here’s What Happened
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Hold” from Analysts